Drug Profile
Research programme: PDE IV inhibitors - elbion NV
Latest Information Update: 22 Aug 2007
Price :
$50
*
At a glance
- Originator elbion NV
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 05 Dec 2006 4AZA Bioscience has merged with elbion to form elbion NV
- 02 Dec 2005 Preclinical trials in Inflammation in Belgium (unspecified route)